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chromatographyAbstract In this study an effective method was developed to assay erythromycin ethylsuccinate for
an oral suspension dosage form. The chromatographic separation was achieved on an X-Terra
C18 analytical column. A mixture of acetonitrile–ammonium dihydrogen phosphate buffer
(0.025 mol L-1) (60:40, V/V) (pH 7.0) was used as the mobile phase, efﬂuent ﬂow rate monitored
at 1.0 mL min1, and UV detection at 205 nm. In forced degradation studies, the effects of acid,
base, oxidation, UV light and temperature were investigated showing no interference in the peak
of drug. The proposed method was validated in terms of speciﬁcity, linearity, robustness, precision
and accuracy. The method was linear at concentrations ranging from 400 to 600 lg mL1, precise
(intra- and inter-day relative standard deviations <0.65), accurate (mean recovery; 99.5%). The
impurities and degradation products of erythromycin ethylsuccinate were selectively determined
with good resolution in both the raw material and the ﬁnal suspension forms. The method could
Figure 1 Chemical structure of er
1080 F. Kamarei et al.be useful for both routine analytical and quality control assays of erythromycin ethylsuccinate in
commercial powder for an oral suspension dosage form and it could be a very powerful tool to
investigate the chemical stability of erythromycin ethylsuccinate.
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Erythromycin is produced by a strain of Streptomyces erythrae-
us and belongs to the macrolide group of antibiotics. It is basic
and readily forms salts with acids. Erythromycin is an antibiotic
that prevents protein synthesis at bacterial ribosomes, resulting
in the death of the organism. Erythromycin is used for the treat-
ment of pneumonias, streptococcal pharyngitis, skin infections
and erythrasma. However, erythromycin is a basic compound
which is degraded to inactive anhydrous erythromycin in acidic
ﬂuids. Hence, ester type prodrugs are preferred and used for oral
administration (Bryskier et al., 1993). Erythromycin ethylsucci-
nate (EES), a prodrug of erythromycin, belongs to macrolide
antibiotics (Fig. 1) and EES is antibacterially inactive and only
becomes effective after it is hydrolyzed to erythromycin in plas-
ma and other body ﬂuids (Kokkonen et al., 1991). EES has been
formulated in both liquid and solid dosage forms for oral
administration. EES is hydrolyzed in aqueous solutions (Stef-
fansson and Bundgaard, 1989), therefore, commercial products
are formulated as powder or granulate forms for reconstitution.
EES is absorbed intact and hydrolyzed in the circulating blood
to the active form (Deicke and Su¨verkru¨p, 2000). At present,
ofﬁcial methods of the United States and British Pharmacopeia
for assay determination of EES in powder for oral suspension
dosage form involve the use of a microbiological method
(USP, 2009; British Pharmacopoeia, 2009). The stability indi-
cating method is a method that identiﬁes the degradation prod-
ucts of analytes (Vaucher et al., 2009). Since the microbiological
assay is not stability-indicating (Croteau et al., 1987), the pres-
ence of erythromycin base and any related degradation products
in raw material or dosage forms of EES cannot be established.
Literature survey reveals several analytical methods for theythromycin ethylsuccinate.determination of EES in pharmaceutical preparation and bio-
logical ﬂuids. These methods are chromatographic techniques,
such as; HPLC–ECD (Croteau et al., 1987), HPLC–UV (Cachet
et al., 1992; Wardrop et al., 2000; Nasr and Stanley, 1998;
Chepkwony et al., 2000) as well as HPLC–MS (Gu et al., 2006).
In the present research a very simple and rapid isocratic
RP-HPLC method which can be used for the routine analysis
of EES for oral suspension was developed. The proposed
method was validated with respect to speciﬁcity, linearity, pre-
cision, accuracy and robustness. In addition, stress testing of
the drug was also conducted, as required by the International
Conference on Harmonization (ICH, 2003) to support the suit-
ability of the method.
2. Experimental
2.1. Reagents
Reference standards of erythromycin ethylsuccinate (with min-
imum purity of 84.05%) were purchased from Anuh pharma
Ltd. (Mumbai, India). Erythromycin base containing (93.5%
erythromycin A), erythromycin B and erythromycin C were
used throughout the study. Ammonium dihydrogen phos-
phate, sodium hydroxide and HPLC grade acetonitrile were
purchased from Merck (Darmstadt, Germany). Ultrapure
water was prepared using a Milli-Q system from Millipore
(Bedford, MA, USA).
2.2. Powder for oral suspension
Three different commercially available products of EES for
oral suspension with nominal potencies of about 200 mg eryth-
romycin (as erythromycin ethylsuccinate) per 5 mL from Hex-
al AG (Holzkirchen, Germany), Loghman Pharmaceutical and
Hygienic Co. (Tehran, Iran) and Chemi darou Industrial Co.
(Tehran, Iran) were used in this study.
2.3. Instrumentation and chromatographic condition
Injection of the samples into high performance liquid chroma-
tography (HPLC) was carried out using a 100-lL Hamilton
(Bonaduz, Switzerland). Separation and quantiﬁcation of ana-
lytes were performed using the Agilent (Wilmington, DE,
USA) 1200 series, consisting of a Rheodyne 77251 injector
(Cotati, CA, USA) equipped with a 100-lL sample loop, a
diode array detector 1200 series, monitoring at 205 nm. The
instrument was linked to HP ChemStation software. An X-
Terra C18 column (250 · 4.6 mm I.D., 5 lm) from Waters
(Dublin, Ireland) was employed at an ambient temperature.
A mixture of acetonitrile and 0.025 mol L1 ammonium dihy-
drogen phosphate buffer at a ratio of (60:40 V/V), (pH 7.0)
was used in this study. The apparent pH was also adjusted
to 7.0 with 10% (W/V) sodium hydroxide solution. The ﬂow
rate of the mobile phase was 1 mL min1.
Figure 2 Chromatogram of a synthetic mixture of (1) erythromycin C, (2) erythromycin A, (3) erythromycin B, (4) erythromycin
ethylsuccinate. Experimental condition: ammonium dihydrogen phosphate buffer: acetonitrile (40:60), pH 7.0; UV detection: 205 nm; ﬂow
rate: 1.0 mLmin1.
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2.4.1. Standard preparation
The working standard solution of erythromycin ethylsuccinate
(500 lg mL1) was prepared in a volumetric ﬂask by dissolving
EES in a small portion of acetonitrile, and then diluting with
the mobile phase to volume. The known potential impurities
were also added in the standard solution for the purity test
of bulk drug.
2.4.2. Sample preparation
A portion of the powder for oral suspension equivalent to
50 mg of EES was weighed and transferred into a 100-mL vol-
umetric ﬂask. Then 20 mL of acetonitrile was added. The mix-
ture was then sonicated for 5 min, and adjusted to volume with
mobile phase and mixed well.
2.4.3. Degradation study
EES at a concentration of 2000 lg mL1 was used in all the
degradation studies. The samples were exposed to stress condi-
tions in 0.1 N HCl, 0.1 N NaOH and 3% (W/V) H2O2. After
the completion of the process, the solutions were diluted at
the ratio of 1:4 with mobile phase. In order to examine thermal
and photo degradation processes, the commercial powder for
oral suspension was exposed to 70 C and daylight ﬂuorescent
lamp conditions. Following the completion of the process,
samples were prepared as described in the previous section.
3. Results and discussion
3.1. Optimization of the HPLC condition
The chromatographic conditions were optimized with respect
to resolution, speciﬁcity and analysis duration. Acceptable sep-
arations were obtained using an X-Terra C18 (250 · 4.6 mmI.D., 5 lm) column. The effects of pH (5.5–7.5), ionic strength
(0.025–0.05 mol L1) and different mobile phase ratio were
investigated using an ammonium dihydrogen phosphate buf-
fer. The best result in terms of peak symmetry, resolution
and retention time was obtained using acetonitrile:buffer
(60:40), as mobile phase. In this case the buffer of mobile phase
was 0.025 mol L1 of ammonium dihydrogen phosphate and
the ﬁnal pH of the mobile phase was also adjusted to 7.0 with
10% (W/V) sodium hydroxide solution. In fact, at lower pH
(<5.5) the peak symmetry of the EES was severely affected
on most of the higher loaded stationary phases and fronting
was observed. On the other hand, higher pH (>7.5) was not
considered in the experiments as it lowers the stability of the
stationary phase. Therefore, pH 7.0 was adopted in subsequent
experiments. The detection was carried out at 205 nm. In the
optimized conditions described above, EES was well separated
from the main hydrolysis product, erythromycin A as well as
minor impurities (erythromycin B and erythromycin C) in
samples. Fig. 2 shows a typical chromatogram of a synthetic
mixture of the four mentioned compounds.
3.2. Degradation of EES
The capability of stability-indicating assay was examined
through stress testing. Standards, samples and placebo were
subjected to the following conditions: acidic, basic and oxida-
tive degradation using 0.1 N HCl, 0.1 N NaOH and 3% H2O2,
respectively. For the thermal and photo degradation, 70oC and
daylight ﬂuorescent lamp radiance were applied, respectively.
In acidic, basic and oxidative degradation processes
2000 lg mL1 of EES was prepared in aforementioned solu-
tion for 4 h at 25 C, and then the solutions were diluted at
1:4 ratio with mobile phase. Finally, 100 lL of the obtained
solutions was injected into the HPLC system for subsequent
analysis. Fig. 3A shows the chromatogram of EES working
standard (500 lg mL1) and Fig. 3B–D show the chromato-
Figure 3 Chromatograms of (A) working standard of EES (500 lg mL1), (B) acid hydrolysis-degraded, (C) base hydrolysis-degraded,
(D) oxidative-degraded. Experimental condition: ammonium dihydrogen phosphate buffer: acetonitrile (40:60), pH 7.0; UV detection:
205 nm; ﬂow rate: 1.0 mL min1.
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tions, respectively. Fig. 4A shows the chromatogram of the
sample (500 lg mL1) before exposure to the thermal and
photo degradation conditions. In order to investigate the ther-
mal degradation of sample, a small portion of commercial
samples of powder for oral suspension were kept at 70 C
for 4 h. Photo degradation was performed as well for the same
samples by exposing them to daylight ﬂuorescent lamp radia-
tion for 24 h at 25 C. The results showed that the degradation
rate of these products were slowly in initial hours (Fig. 4B and
C). The placebo was submitted to the same degradation condi-
tions in order to demonstrate no interference. All degradation
studies showed that the degradation products were well sepa-rated from EES peak, conﬁrming the stability indicating capa-
bility of the method.
3.3. Stability of EES in solution
The stability of EES in mobile phase was investigated by ana-
lyzing the standard of EES (500 lg mL1) containing
500 lg mL1 of erythromycin A (internal standard) at 0, 15,
30, 45, 60, 90, 120 and 140 min, after preparation at ambient
temperature. Fig. 5 shows that after 120 min, the areas of
peaks decreased. This can be explained by the fact that the
hydrolysis of EES is time dependent. Therefore, the working
standard should be used freshly.
Figure 4 Chromatogram of (A) sample (hexal) (500 lg mL1), (B) thermal-degraded, (C) photo-degraded. Experimental condition:
ammonium dihydrogen phosphate buffer: acetonitrile (40:60), pH: 7.0; UV detection: 205 nm; ﬂow rate: 1.0 mL min1.
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The proposed method was further validated for speciﬁcity,
linearity, accuracy, precision, robustness and system suitability
according to ICH guidelines (ICH, 1995).3.4.1. Speciﬁcity
The speciﬁcity of the analytical method was determined by
comparing the results from an analysis of samples containingimpurities, degradation products, or excipients with those ob-
tained from samples without the above mentioned cases. As
can be seen in the chromatograms of degradation studies, all
degradation products were separated from EES peak. In order
to conﬁrm this result, a given portion of placebo was prepared
in mobile phase and injected onto the chromatograph. Results
indicate that excipients have no interference with EES. The
homogeneity and peak purity of the EES peak in three expired
product samples were estimated based on a photodiode-array
(PDA) scan from 210 to 400 nm. Peak purity factor was
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Figure 5 Proﬁle of EES stability in mobile phase. Experimental condition: ammonium dihydrogen phosphate buffer: acetonitrile (40:60),
pH: 7.0; UV detection: 205 nm; ﬂow rate: 1.0 mL min1.
Table 1 Figures of merit of the proposed method.
DLR (lg mL1) Regression equation r2
400–600 Y= 18.65aX  424b 0.9930
a SD and RSD of slope; 0.156, 0.85.
b SD and RSD of intercept; 2.98, 1.46.
Table 2 Accuracy assessment of the proposed method for
EES assay.
Working standard range (%) Cadded (lg mL
1) % Recoverya SDa
80 400 99.50 0.381
100 500 99.84 0.141
120 600 99.89 0.202
a Standard deviation (SD) and % recovery were obtained at mean
value of four replicate measurements.
Table 3 System suitability parameters.
Parameter EES Preferable levels
K0 3 2–5
A 1.21 1.0–2.0
Rs 1.86 >1.5
N 2560 >2500
As 0.97 <1.5
Table 4 HPLC assay results of commercial EEs powder for
oral suspension.
Product testeda USP assay
limitb %
Label claim (mg/5 mL) % Found ± SD
Hexal 90–120 200 97.43 ± 0.76
Loghman 90–120 200 94.76 ± 0.52
Chemi darou 90–120 200 95.91 ± 0.43
a Samples were prepared as described in Section 2.
b USP (2009).
1084 F. Kamarei et al.obtained which was 995.045 and Purity threshold calculated by
PDA software automatically which was 997.692.
3.4.2. Linearity
Linearity of system was evaluated by the analysis of three rep-
licates of ﬁve concentrations of standard solutions (ranging
from 400 to 600 lg mL1). Linear dynamic range (LDR),
regression equation and correlation coefﬁcient (r2) are given
in Table 1.
3.4.3. Accuracy
In order to evaluate the recovery of analyte, accuracy study
was performed by spiking three known amounts of EES in pla-
cebo suspension (ranging from 80% to 120% working stan-
dard concentration, 500 lg mL1). Three samples were
prepared at each of these concentrations. The recovery of
added drug was calculated by comparing the area of EES peak
of the test sample with that of the standard solution. The
results are given in Table 2.
3.4.4. Precision
Precision of an analytical procedure expresses the closeness of
agreement between a series of measurements obtained from
multiple samples. The precision is usually investigated at three
levels: repeatability, intermediate precision and reproducibility
(Chan et al., 2004). The repeatability (intraday) and reproduc-
ibility (interday) were studied based on the peak area at
500 lg mL1 concentration by injecting ﬁve samples onto the
chromatograph. The precisions of 0.64 and 0.65 were obtained
for intra and inter day, respectively.3.4.5. Robustness
The robustness of an analytical procedure is a measure of its
capacity to remain unaffected by small but deliberate varia-
tions in the analytical procedure parameters. The robustness
Development of a stability-indicating high performance liquid chromatography method for assay of erythromycin 1085of an analytical procedure provides an indication of its reliabil-
ity during normal use (Chan et al., 2004). The robustness of
proposed method was evaluated by keeping chromatographic
conditions constant while the following differences were incor-
porated into experiments:
1) Changing ammonium dihydrogen phosphate buffer
(35%, V/V) and acetonitrile (65%, V/V) composition
in mobile phase.
2) Increasing the ﬂow rate of mobile phase from 1.0 to
1.5 mL min1.
3) Using another column (Agilent, C18, 250 · 4.6 mm I.D.,
5 lm), standard solution was injected six times in repli-
cate for each change. All the parameters of system suit-
ability were recorded and found to be within acceptable
limits. Recoveries and relative standard deviations were
calculated for EES during each change and found to be
99.5–99.99% and <1.0%, respectively.
3.4.6. System suitability
The system suitability parameters including asymmetric factor
(As), resolution (Rs), selectivity (a) and capacity factor (K),
listed in Table 3, were obtained by six replicates. All parame-
ters were acceptable with good speciﬁcity for the stability
assessment of EES.
3.4.7. Assay of EES in powder for oral suspension
Three different commercially available powder products for
oral suspension were obtained and assayed as described in
Section 2. The assay results of EES for oral suspension dosage
forms were comparable with the label value claimed. The
results are shown in Table 4.
4. Conclusion
Proposed isocratic RP-HPLC method can be used as a stabil-
ity indicating assay as well as for the potency assay of EES for
oral suspensions. This method offers the separation of EES
from related substances, impurities and degradation products
simultaneously. The most important advantage of the pro-
posed method in comparison with pharmacopeia (USP,
2009; British Pharmacopoeia, 2009) is using a speciﬁc chro-
matographic method. Proposed method can be replaced by a
tedious, time-consuming and non-speciﬁc microbiological as-
say method (Bioassay). The method has been validated andit has been shown that it is reliable, linear, and precise as well
as robust with minor variations in chromatographic parame-
ters. Therefore, it can be applied for both routine analytical
and quality control assay of erythromycin ethylsuccinate in
commercial powder for oral suspension and it could be a very
powerful tool to investigate the chemical stability of erythro-
mycin ethylsuccinate.Acknowledgements
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